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Background: Some recently emerged lipid-lowering therapies are currently restricted to patients with
homozygous familial hypercholesterolemia (HoFH), and studies are underway to also assess these
therapies in patients with ‘severe heterozygous FH (HeFH)’. However, no uniform deﬁnition of ‘severe
HeFH’ exists, although untreated low-density lipoprotein cholesterol (LDL-C) levels above 8 mmol/L
(309 mg/dl) have been historically used to deﬁne this phenotype. Our aim was to deﬁne severe HeFH, to
establish its prevalence and CVD risk, and to study the relative contribution of classical risk factors to
CVD risk in HeFH patients.
Methods and results: We analysed a cohort of 14,283 patients with molecularly deﬁned HeFH, identiﬁed
by the national FH screening programme in the Netherlands. Age and gender speciﬁc percentiles of
untreated LDL-C were determined. The percentile corresponding to an LDL-C level of 8 mmol/L (309 mg/
dL) in men aged 36e40 years (90th percentile) was selected as the cut-off value for severe HeFH. By
applying this percentile-criterion to the whole cohort, 11% of the HeFH patients could be considered as
having severe HeFH. Combined with an estimated HeFH prevalence of 1:300 in the Netherlands, this
would translate into a prevalence of approximately 1:3,000 for severe HeFH. CVD risk was signiﬁcantly
increased in severe HeFH patients compared to non-severe HeFH patients (adjusted hazard ratio: 1.25
[95% CI: 1.05e1.51], p¼ 0.015). In line, male gender, increased age, increased BMI, smoking, hypertension,
diabetes, high LDL-C and low high-density lipoprotein cholesterol were independent CVD risk factors in
HeFH per se.
Conclusions: We changed the commonly used static LDL-C level of 8 mmol/L for the identiﬁcation of
severe HeFH into an age and gender corrected percentile. This deﬁnition would theoretically result in a
prevalence of 1:3,000 for severe HeFH. Patients with severe HeFH are at increased CVD risk compared to
non-severe HeFH patients, which underscores the need for more aggressive LDL-C lowering these
patients.
 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Familial hypercholesterolemia (FH) is a prevalent autosomal
dominant disorder of lipoprotein metabolism, caused by mutations
in the genes encoding for the low-density lipoprotein (LDL) re-
ceptor, apolipoprotein B (ApoB) or proprotein convertase subtilisin/
kexin-type 9 (PCSK9). Patients with FH are characterized by
elevated serum LDL-cholesterol (LDL-C) levels and an increased riskMedicine, Academic Medical
sterdam, The Netherlands.
nd Ltd. All rights reserved.for premature cardiovascular disease (CVD) [1]. LDL-C levels vary
widely amongst FH patients, and patients with LDL-C levels at the
upper extreme tail of the distribution are considered to suffer from
‘severe FH’.
In literature, heterozygous FH (HeFH) patients with a plasma
LDL-C level above 8 mmol/L (309 mg/dL), prior to lipid-lowering
therapy (LLT), have been considered to suffer from severe HeFH.
This level is, however, not adjusted for age and gender, and this
might be particularly important given the fact that LDL-C levels are
not uniform across characteristics such as age.
The exact prevalence and CVD risk of severe HeFH are unknown.
These issues are of particular interest given the potential market
authorisation of novel therapeutic LDL-C lowering agents for
Table 1
Demographic and clinical characteristics of 14,283 heterozygous FH patients.
Male gender e no. (%) 6,848 (48.0)
Age (years) e mean (SD) 38.33 (21.16)
Body mass index (kg/m2) e mean (SD) 23.67 (5.10)
Current smoking e no. (%) 3,731 (26.7)
Hypertension e no. (%) 1,619 (11.3)
Diabetes mellitus e no. (%) 401 (2.8)
Lipid-lowering therapy e no. (%) 5,381 (37.7)
Total cholesterol (mmol/L) e mean (SD) 5.97 (6.47)
HDL-cholesterol (mmol/L) e mean (SD) 1.21 (1.88)
LDL-cholesterol (mmol/L) e mean (SD) 4.13 (1.38)
Untreated LDL-cholesterol (mmol/L) e mean (SD) 5.17 (1.98)
- Non-severe HeFH patients e mean (SD) 4.72 (1.40)
- Severe HeFH patients e mean (SD) 8.84 (2.15)
Triglycerides (mmol/L) e median [IQR] 1.1 [0.75e1.64]
Cardiovascular disease in medical history e no. (%)a 1,310 (9.2)
HDL, high-density lipoprotein; LDL, low-density lipoprotein; no., number; SD,
standard deviation.
a Deﬁned as myocardial infarction, coronary bypass surgery, percutaneous
transluminal coronary angioplasty, angina pectoris and/or ischaemic stroke in the
medical history.
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non-severe HeFH patients has not been quantiﬁed so far.
Although it is pivotal to emphasize that CVD risk in HeFH is
largely driven by LDL-C levels, CVD risk also varies widely amongst
patients with HeFH. These interindividual differences are probably
caused by the aggregate of variation in LDL-C levels and the total
burden of other risk factors, such as smoking, hypertension and
diabetes [2,3]. It is, however, not fully elucidated what the relative
contribution of these latter factors is in HeFH patients.
Therefore the aims of the current studywere to: 1) deﬁne severe
HeFH and establish its prevalence; 2) describe the CVD risk in pa-
tients with severe HeFH compared to non-severe HeFH patients; 3)
study the contribution of classical risk factors to CVD risk in HeFH
patients. We studied an unprecedented number of patients with
molecularly deﬁned HeFH to answer these important clinical
questions. Here we present our results.
2. Methods
2.1. Study population and collection of data
All data in the current study were collected for the FH screening
program in the Netherlands. The aim of this nationwide and gov-
ernment subsidized cascade screening program is to identify all FH
patients. The screening cascade starts with the identiﬁcation of a
carrier of an FH mutation (“index patient”), and subsequent anal-
ysis in ﬁrst degree relatives of this patient. A blood sample is drawn
to perform DNA analysis and since 2004, blood is withdrawn in a
fasting state to also measure lipids and lipoproteins. This is a cross-
sectional analysis and as such, all data used for this study were
collected at the moment the individual was visited by the genetic
ﬁeld worker. As a consequence, only persons that were alive could
participate in the screening program. Subjects were eligible for the
current study if a molecular defect underlying FH was identiﬁed.
Patients were excluded in case a lipid proﬁle was not available or if
no data were present on the use of LLT. Homozygous patients were
excluded as well. All patients provided written informed consent.
This study was approved by the Medical Ethical Committee of the
Academic Medical Centre.
2.2. Lipid proﬁle and mutation analysis
The lipid proﬁle was measured with the LDX-analyser (Choles-
tech Corporation, Hayward, USA) [4]. LDL-C levels were subse-
quently calculated with the Friedewald formula, unless
triglycerides were above 4.5 mmol/L [5]. We calculated untreated
LDL-C levels in patients using LLT at the time of screening, on the
basis of dose and type of medication. The correction factors for each
therapy, and the scientiﬁc foundation for these, are provided in
Supplement A. The maximal LDL-C lowering efﬁcacy of LLT was
considered to be 50%.
DNA of the tested individuals was isolated from 10 ml of freshly
collected blood containing EDTA as anticoagulant. The method of
mutation analysis has been described previously [6,7].
2.3. Deﬁnition of severe HeFH
We redeﬁned severe HeFH while applying age and gender
speciﬁc percentiles with the data of the current study (see
Supplement B). Males between 36 and 40 years were considered to
be most frequently represented in our and previous cohort studies
on severe HeFH and we therefore established the percentile cor-
responding to the LDL-C level of 8 mmol/L (309 mg/dL) in these
speciﬁc patients. We transposed this percentile to the remainder ofthe total population, thereby deﬁning an age and gender speciﬁc
LDL-C level for the deﬁnition of “severe HeFH”.
2.4. Cardiovascular disease
CVD was deﬁned as: myocardial infarction; coronary artery
bypass surgery; percutaneous transluminal coronary angioplasty;
angina pectoris; and/or ischaemic stroke.
2.5. Statistical analyses
Differences in baseline characteristics between non-severe
HeFH and severe HeFH patients were evaluated using logistic
(dichotomous variables) and linear (continuous variables) regres-
sion models.
We constructed cumulative survival curves for patients with
severe HeFH as well as for patients not suffering from severe HeFH
by the KaplaneMeier method. Differences between the curves
were tested with the log-rank test. Cox proportional hazards
models were used to estimate hazard ratios (HRs) while adjusting
for gender, birth-year and LLT (time-dependent). To account for
family ties, the Cox model was ﬁtted with a random intercept per
family. Follow-up started at birth and ended for each individual at
the date of the ﬁrst CVD event or censoring (date when subject was
visited for enrolment in the screening program), whichever came
ﬁrst. Since several potential confounders could only bemeasured at
screening, we also adjusted for these factors by means of a logistic
regression analysis.
The association between CVD and demographic and clinical
characteristics was ﬁrst explored using univariate logistic regres-
sion analysis. The following variables were entered into the ana-
lyses: gender, age, body mass index (BMI), smoking, hypertension,
diabetes mellitus and lipid proﬁle. Stepwise multiple logistic
regression analysis was used to assess the independent effect of
these variables on the presence of CVD.
All logistic and linear regression analyses were performed using
the generalized estimating equation method to account for corre-
lations within families. The exchangeable correlation structure was
used for these models.
Continuous variables with a skewed distribution were log
transformed before the analyses. A p-value less than 0.05 was
considered to be statistically signiﬁcant. Analyses were carried out
using SPSS 20 forWindows (IBM Software, NY, USA) and R Statistics
3.0.1.
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3.1. Study population
From January 1994 until November 2013, a total of 64,216 in-
dividuals underwent DNA testing for HeFH and a causative muta-
tion was identiﬁed in 26,787 individuals (42.1%). Lipid proﬁles and
data regarding LLT was present for 14,283mutation carriers (53.3%)
and these comprised our study population. Demographic and
clinical characteristics are provided in Table 1. Age ranged from 0 to
93.7 years with a mean age of 38.3 years (standard deviation
(SD) 21.2), 6,850 (48.0%) were male and CVDwas present in 1,310
(9.2%) patients.
3.2. Deﬁnition and prevalence of severe HeFH
In males between 36 and 40 years, 8 mmol/L (309 mg/dL) was
found to correspondwith the 90th percentile. A total of 1,580 (11.1%;
[95% conﬁdence interval: 10.6e11.6]) individuals met our deﬁnition
of severe HeFH while applying the percentile-criterion for the
remainder of the HeFH population. Combined with the estimated
prevalence of HeFH in the Netherlands (1:300) [8,9], the prevalence
of severe HeFH in the Dutch population is anticipated to be
approximately 1:3,000. Given an approximate population size of
16,7 million in the Netherlands, the total number of patients with
severe HeFH is estimated to be at 6,185 individuals in our country.
3.3. Severe HeFH and risk for CVD
Mean age at diagnosis (38.3 21 versus 38.4 21, p¼ 0.98) and
gender distribution (48.0% versus 47.9%, p ¼ 0.95) were similar in
severe HeFH patients and non-severe HeFH patients. BMI was
signiﬁcantly higher in patients with severe HeFH compared to non-
severe FH patients (24.3 5 versus 23.6 5, p< 0.001), and a lower
prevalence of diabetes mellitus was present in severe HeFH (1.7%
versus 2.9%, p ¼ 0.007). Smoking was more prevalent in severe
HeFH patients (32.5% versus 25.9%, p< 0.001), while the prevalence
of hypertension did not differ between the two groups (11.1% versus
11.4%, p ¼ 0.76). Clinical manifestations of CVD were signiﬁcantly
more prevalent amongst patients diagnosed with severe HeFH
compared with patients with non-severe HeFH (10.8% [n ¼ 171] vs.
9.0% [n ¼ 1,139] respectively, p ¼ 0.018). The cumulative CVD-freeFig. 1. KaplaneMeier incidence estimates for severe and non-severe HeFH patients.survival was signiﬁcantly shorter for patients with severe HeFH
as compared to patients with non-severe HeFH (Fig. 1: p ¼ 0.01; HR
adjusted for family relations: 1.22 [95% CI: 1.02e1.45], p ¼ 0.026;
HR adjusted for birth-year, gender, use of LLT [time-varying] and
family relations: 1.25 [95% CI: 1.05e1.51], p ¼ 0.015). The increased
CVD risk in severe HeFH remained statistically signiﬁcant after
adjustment for age, gender, BMI, hypertension, diabetes mellitus,
smoking and family relations by means of a multivariate logistic
regression model, (adjusted OR: 1.36 [95% CI: 1.09e1.69],
p ¼ 0.007).
3.4. Risk factors in HeFH patients
A total of 1,310 of the 14,283 patients (9.2%) had experienced an
atherosclerotic event. In the univariate logistic regression analyses
male gender, increased age, increased BMI, smoking, hypertension,
diabetes mellitus, and high LDL-C and triglyceride levels were
found to be associated with an increased risk for atherosclerotic
events (Table 2). High-density lipoprotein cholesterol (HDL-C) was
inversely associated with CVD risk. After stepwise backward elim-
ination, multiple logistic regression analysis identiﬁedmale gender,
increased age, increased BMI, smoking, hypertension, diabetes,
high LDL-C and low HDL-C as independent risk factors for CVD.
4. Discussion
In this study we set out to redeﬁne severe HeFH and to establish
its prevalence and CVD risk. Severe HeFH has previously been
deﬁned using the criteria for LDL apheresis, i.e. an LDL-C level of
8 mmol/L (309 mg/dL) or above, prior to therapy [10]. However,
due to the signiﬁcant impact of age and gender on LDL-C levels [11],
it is not reasonable to apply this ﬁxed cut-off value to all HeFH
patients since this would result in a skewed distribution. More
speciﬁcally, it would result in a low prevalence of severe HeFH in
young patients, who, generally speaking, are characterized by
lower LDL-C levels compared to elderly patients. Since some of the
novel LDL-C lowering therapies are likely to be reserved for pa-
tients with severe HeFH, applying the ﬁxed 8 mmol/L (309 mg/dL)
will lead to undertreatment of young patients with severe HeFH.
This is exempliﬁed by the ﬁnding that only 5.7% of the male HeFH
patients in the range between 21 and 30 years met the criterion ofTable 2
Risk factors for CVD in heterozygous FH patients.
Univariable Multivariable
OR 95% CI p-value OR 95% CI p-value
Male gender 1.72 1.53e1.92 <0.001 2.44 2.07e2.88 <0.001
Age (years) 1.08 1.08e1.09 <0.001 1.08 1.08e1.09 <0.001
Body mass index
(kg/m2)
1.13 1.12e1.15 <0.001 1.04 1.03e1.06 <0.001
Smoking 1.70 1.50e1.94 <0.001 1.59 1.36e1.86 <0.001
Hypertension 8.02 7.08e9.07 <0.001 2.38 2.01e2.82 <0.001
Diabetes mellitus 6.40 5.21e7.86 <0.001 1.37 1.03e1.82 0.03
HDL-cholesterol
(mmol/L)
0.55 0.46e0.65 <0.001 0.61 0.48e0.77 <0.001
LDL-cholesterol
(mmol/L)a
1.16 1.13e1.19 <0.001 1.08 1.04e1.12 <0.001
Triglycerides
(mmol/L)b
1.76 1.59e1.94 <0.001 e e e
Cardiovascular disease is deﬁned as myocardial infarction, coronary bypass surgery,
percutaneous transluminal coronary angioplasty, angina pectoris and/or ischaemic
stroke in the medical history.
OR, odds ratio; CI, conﬁdence interval; HDL, high-density lipoprotein; LDL, low-
density lipoprotein.
a Untreated LDL-cholesterol.
b Logtransformed before analyses.
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aged 60 years or older were found to have LDL-C levels above
8 mmol/L (309 mg/dL). This difference underscores the need for an
age and gender adjusted deﬁnition and therefore we suggest using
our deﬁnition of the 90th percentile of untreated LDL-C in HeFH
patients to identify severe HeFH patients. Using this deﬁnition,
patients that would meet currently used criteria for severe HeFH
only at a later age, will likely be diagnosed earlier in live, enabling
more prevention years in the ﬁght against premature CVD. Based
on our deﬁnition of the 90th percentile for age and gender, and
taken into account that approximately 1:300 persons in the
Netherlands suffer from HeFH, we estimated the prevalence of
severe HeFH in the Netherlands to be approximately 1:3,000,
which is considerably higher than the prevalence reported in
previous studies performed in the United States (1:10,000 to
1:50,000) [12]. It should be noted, however, that in the latter study
only patients with LDL-C levels above 8 mmol/L (309 mg/dL) were
considered to suffer from severe HeFH.
Our ﬁnding that patients with severe HeFH are at increased risk
for CVD compared to thosewith non-severe HeFH is in linewith the
commonly appreciated direct causal relationship between LDL-C
and CVD risk. It should urge clinicians to aggressively lower LDL-
C in these high risk patients and to start preferably at young age
[13]. Despite the absence of trials of LDL-C reduction on CVD events
in the young, there is increasing evidence that decreased LDL-C
levels in young adulthood are associated with reduced prevalence
of CVD at later age [14,15]. Moreover, LDL-C reduction in children
and adolescents has been shown to result in a decrease in sub-
clinical atherosclerosis [16,17], which has resulted in guidelines
advocating treatment of children with FH [18,19].
Secondly, we determined the contribution of the classical risk
factors to CVD risk in our large HeFH cohort. Male gender, increased
age, smoking, hypertension, diabetes, increased BMI, increased
LDL-C and low HDL-C were signiﬁcantly and independently asso-
ciated with the presence of CVD. On average, these cardiovascular
risk factors are in line with previous results [3] and with those in
the general population [20,21], although the relative contribution
differs. This can be explained by differences between studies with
regard to study design, the population of patients studied and the
deﬁnition of risk factors. Ferrieres and colleagues investigated the
prevalence and contributions of risk factors in FH patients with a
speciﬁc mutation who were referred to a Lipid Clinic [3]. It was
found that very low density lipoprotein (VLDL-) cholesterol, LDL-C
and age were independent CVD risk factors inwomen. In men, only
age and HDL-C were independently associated with CVD. In
contrast to our results, smoking, diabetes and hypertension did not
contribute to CVD risk in this Canadian study. The fact that the
traditional risk factors were not found to be associated with CVD
outcome is likely to be the result of the relatively small number of
patients studied.
Somemethodological aspects of our study merit discussion. The
most important limitation is the cross-sectional nature of our data.
As a result, a causal relationship between risk factors and CVD
cannot be made. However, all factors identiﬁed in this study have
been established as causally related to outcome [20,21] and we
consequently deem our ﬁndings to be real and not attributable to
spurious association. Second, one of the inclusion criteria of our
study was that subjects were tested for FH in the screening pro-
gram. As a consequence, subjects that would have been tested in
the screening program but already died before, were of course, not
included in our study population. Therefore, survival bias probably
leads to an underestimation of CVD events in the FH patients.
Because this will likely be more pronounced in the group of pa-
tients with severe HeFH, the prevalence of severe HeFH will also be
underestimated.5. Conclusion
While applying our new age and gender corrected deﬁnition of
severe HeFH we found that the prevalence of this subphenotype of
FH is approximately 1:3,000 in the Netherlands. The notion that
these patients are at sharply increased CVD risk and that traditional
factors do contribute to this risk suggest that aggressively lowering
LDL-C instituted at young age may be required, in addition to
speciﬁcally targeting the traditional risk factors.
A number of novel lipid lowering therapies [22e24] will prob-
ably enter the clinical arena within the near future. Given their
costs, these new agents will probably be reserved for patients with
homozygous FH and severe HeFH. It is therefore pivotal to deﬁne
the latter condition, for both policy makers as well as for guideline
committees.
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